TargaZyme, Inc. Appoints Christopher Calhoun to Business Advisory Board

SAN DIEGO, CA--(Marketwired - June 03, 2014) - TargaZyme, Inc. (formerly America Stem Cell, Inc. or the "Company"), a clinical-stage biopharmaceutical company developing enzyme platform technologies/products to improve efficacy outcomes for cell therapy and cancer immunotherapy, announced today that it has appointed Christopher Calhoun to its Business Advisory Board. 

Chris Calhoun is a co-founder of Cytori Therapeutics. He has served as its Vice-Chairman/Director and Chief Executive Officer.

Lynnet Koh, Chairman & CEO of TargaZyme, Inc., stated "Mr. Calhoun is a visionary entrepreuneur, a proven public company CEO with a successful track record with major capital raising in the public markets, global product development and global strategic partnerships. Mr. Calhoun's expertise is particularly valuable to TargaZyme as it moves into its next phase of business evolution."

Mr. Calhoun commented, "I am delighted to work with TargaZyme because it is leading the advancement into next generation innovation in cell therapy. To date, the majority of clinical stage cell therapy based companies are focused on primary applications of cells. However, value will migrate toward second and third generation technology that will improve the targeting, engraftment, safety, and specific mechanisms of action that will result in substantially better outcomes for patients as well as reducing the overall cost of care. Now moving into later stage clinical trials, TargaZyme's potentially revolutionary enzyme product has the potential to dramatically improve cell targeting and engraftment for cell-based therapies including immunotherapies, cancer therapy and mesenchymal cell based repair and regeneration therapies. Lynnet Koh has assembled a world-class team that matches her global vision for transforming patient care and delivering value to shareholders. It is a tremendous honor to have the opportunity to work with this team and this company as it matures into late stage clinical trials and ultimately a global commercial leader in the field."

About TargaZyme, Inc.
TargaZyme, Inc. is a privately held biotechnology company based in San Antonio, TX with additional offices in San Diego, CA and Basel, Switzerland. Its key technology platforms (TZ101 and TZ102) are designed to improve the homing and engraftment of a wide variety of therapeutic cells to target tissues. Applications in development include hematopoietic stem cell transplants, immunotherapies for solid tumors, cell therapies to ameliorate graft-versus-host and autoimmune diseases, and cell therapies for ischemic diseases such as myocardial infarction and stroke. TargaZyme has partnerships and collaborations with Kyowa Hakko Kirin and Florida Biologix, as well as various medical research institutions including The University of Texas MD Anderson Cancer Center, Wake Forest University, Stanford, UCLA, Oklahoma Medical Research Foundation, Texas Transplant Institute, Case Western/University Hospitals, Scripps Hospitals, Fred Hutchinson Cancer Research Center, University of California San Diego, Sanford-Burnham Medical Research Institute and Indiana University. Learn more at http://www.TargaZyme.com.